# A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391

> **NCT05634447** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 69 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** Drug: CKD-391, QD, PO

## Key facts

- **NCT ID:** NCT05634447
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-20
- **Primary completion:** 2023-02-27
- **Final completion:** 2023-06-07
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2023-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05634447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05634447, "A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05634447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*